Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077980 | 0.80 | KDM1A (0.51) | KDM1ARCOR1TSHR | |
| SCHEMBL556983 | 0.79 | ADAMTS5 (0.37) | KDM1AALDH1A1 | |
| SCHEMBL533997 | 0.79 | ADAMTS5 (0.37) | KDM1AALDH1A1 | |
| SCHEMBL15767640 | 0.78 | KDM1A (0.51) | KDM1A | |
| SCHEMBL11700667 | 0.78 | KDM1A (0.51) | KDM1A | |
| SCHEMBL1943935 | 0.78 | KDM1A (0.51) | KDM1A | |
| SCHEMBL3739337 | 0.77 | KDM1A (0.40) | KDM1ARCOR1 | |
| SCHEMBL1000359 | 0.77 | KDM1A (0.51) | KDM1ARCOR1TSHRALDH1A1 | |
| SCHEMBL15766918 | 0.77 | KDM1A (0.51) | KDM1ARCOR1TSHRALDH1A1 | |
| SCHEMBL15766917 | 0.77 | KDM1A (0.51) | KDM1ARCOR1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026396-B2 | Processes for the preparation of optically active intermediates | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-7790927-B2 | Using hypochlorite in water in presence of alkali metal hydroxide | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP1B1, CYP2S1 | KDM1A 2949/4885RCOR1 4694/4885CCR2 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.